From our sister brand, Managed Healthcare Executive: Smoothing the pathway for the development and approval of biosimilars is a central strategy of the Trump administration, Congress, and FDA. Here are the top ways FDA will encourage more biosimilar uptake.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%